Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments

Radiation Oncology

Table 3 Summary of selected trials of stereotactic body radiation therapy for lung metastases

Study	No patients	Median dose/no fractions	Median FU mos (range)	Local control rate	Overall survival	Toxicity
Okunieff et al [13]	50	50 Gy/10	18.7 (3.7-60.9)	3-yr 91%	2-yr 50%	G2 6.1%
		48 Gy/6				G3 2%
		57 Gy/3
Norihisa et al [15]	34	48 Gy/4	27 (10-80)	2-yr 90%	2-yr 84%	G2 12%
Norihisa et al [15]	34	60 Gy/5	27 (10-80)	2-yr 90%	2-yr 84%	G3 3%
Le et al [14]	32	15 Gy/1	-	1-yr 54%		G2-G3 4
		20 Gy/1		1-yr 54%		G5 3
		25 Gy/1		1-yr 91%		Dose ≥ 25 Gy
		30 Gy/1		1-yr 91%
				2-yr 67%
Salama et al [16]	61	24 Gy/3	20.9 (3-60.5)	1-yr 67.2%	2-yr 56.7%	G3 3
Salama et al [16]	61	48 Gy/3	20.9 (3-60.5)	2-yr 52.7%	2-yr 56.7%
Rushoven et al [17]	38	60 Gy/3	15.4 (6-48)	2-yr 96%	2-yr 39%	G3 3 (8%)
Ricardi et al [18]	61	45 Gy/3	20.4 (3-77)	2-yr 89%	2-yr 66.5%	G3 1 (1.6%)
		26 Gy/1

ISSN: 1748-717X